UBS Group
UTHR icon

UBS Group’s United Therapeutics UTHR Stock Holding History

UBS Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,700
Closed -$2.34M – 8285
2018
Q2 		$2.34M Buy
+20,700
New +$2.28M ﹤0.01% 3026
2015
Q3 		– Sell
-10,800
Closed -$1.88M – 8645
2015
Q2 		$1.88M Buy
+10,800
New +$1.94M ﹤0.01% 3038

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group's UTHR Position: Q1 2026 in Review

UBS Group increased its United Therapeutics (UTHR) stake by 4.8% in Q1 2026, buying an estimated $5.42M and bringing the position to 236,729 shares worth $140M. The position accounts for 0.02% of the portfolio, ranked #808.

UBS Group first reported a position in UTHR in Q4 2014 and has held it in 46 quarters since. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • UBS Group held 236,729 shares of United Therapeutics worth $140M as of Q1 2026.
  • UBS Group bought 10,880 United Therapeutics shares in Q1 2026, an estimated $5.42M.
  • United Therapeutics made up 0.02% of UBS Group's portfolio in Q1 2026, its #808 holding.
  • UBS Group first reported a position in United Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.